Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the price of USD340 per six-month treatment course for more than 135 eligible countries. This initiative was done with support from the Global Fund to Fight AIDS, Tuberculosis, and Malaria and USAID.
The move has been praised by Médecins Sans Frontières as an important step forward in the fight against TB.
“In a world filled with worrying news, this new agreement is a welcome development and one that will help us move closer to the United Nations High-Level Meeting target of treating 1.5 million people with DR-TB by 2022,” said Dr. Lucica Ditiu, M.D., Executive Director of the Stop TB Partnership.
To read more about Johnson & Johnson and the Stop TB Partnership's announcement on bedaquiline's price reduction, please visit the Stop TB Partnership website here.